- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials -
- Company to Hold Investor Event on Sunday, May 31 with Oncology Experts -
SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present new data from two ongoing Phase 2 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. The Company will present results of picoplatin plus docetaxel/prednisone in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC) and picoplatin plus 5-FU/leucovorin in patients with metastatic colorectal cancer (CRC).
Both presentations will include new, recently obtained, efficacy and safety data, including progression-free survival data, not reflected in the abstracts that will be posted on the ASCO Web site on Thursday, May 14 at 6:00 p.m. Eastern Time. The CRC presentation will be followed by an ASCO poster discussion.
Poster presentation details are as follows:
-- Results of a Phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer Abstract #5140 R. De Jager, L. Roman, N. Lopatkin, P. Karlov, H. Breitz, R. Earhart General Poster Session: Sunday, May 31, from 2:00 p.m.-6:00 p.m. Eastern Time Level 2, West Hall C, Poster #J6 -- Randomized Phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer Abstract
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved